Dr Timothy Yap recently discussed the PETRA trial with ecancer. This is a phase 1/2a clinical trial for saruparib, which is a next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) for patients with advanced solid tumours.

The study focused on individuals with BRCA1/2, PALB2, or RAD51C/D mutations.

The results of the trial showed that saruparib, the selective PARP1 inhibitor being investigated, demonstrated promising activity for patients with certain homologous recombination repair (HRR)-deficient breast cancers while also limiting toxicity.